Lessons from the War on Terrorism - Sharing information is a critical part of security—whether we're protecting travelers from bombs or patients from adulterated medicines. - BioPharm

ADVERTISEMENT

Lessons from the War on Terrorism
Sharing information is a critical part of security—whether we're protecting travelers from bombs or patients from adulterated medicines.


BioPharm International
Volume 23, Issue 3


Laura Bush
In a recent study conducted by the United States Pharmacopeia and the World Health Organization, one third of antimalarial medicines sampled in three African countries failed tests for potency, purity, and dissolution. A few days after that report came out, authorities in Syria arrested 65 people for trafficking in counterfeit versions of cancer drugs in Iraq, Turkey, Lebanon, Iran, and Egypt. Such findings are a harsh reminder of the real risks to drug quality that are present every day in the global pharmaceutical market.

Recent terrorism events serve as another important reminder. The case of Umar Farouk Abdulmutallab, the "Christmas day" terrorist who got a US visa despite having been denied one by Britain and after his own father warned American authorities, makes it clear that sharing information is a critical part of security—whether we are protecting travelers from bombs or patients from adulterated medicines.

Rx-360, a nonprofit industry consortium formed to improve supply chain security, recommends several steps to combat the threats posed by falsifiers. Guy Villax, CEO of Hovione and an Rx-360 board member, explained these proposals in a presentation at the 2009 AAPS conference. In almost all of these measures, pooling data is a central theme.

First, laws should be passed making drug counterfeiting a serious crime with sanctions akin to those for trafficking narcotics, including jail time. Further, individuals and companies involved in counterfeiting should be "de-barred" from future industry activity—in all countries. That requires sharing lists and agreeing to enforce judgments made in other jurisdictions.

Furthermore, inspections of API manufacturing operations should be tripled. For that to be possible with today's limited regulatory resources, Villax says, authorities in countries with robust regulatory systems must trust each others' inspections instead of duplicating them, because that will free up resources to inspect more facilities. Then, if one agency discovers a falsification, that information must be passed on to others, and the licenses for that site should be suspended in all countries, not just in the one whose authorities discovered the problem.

And just as regulators should collaborate on inspections, companies should share supplier auditing data. Rx-360 has a plan to coordinate supplier audits, to reduce the number of site visits, and thus free up time to make audits more thorough.

Furthermore, Rx-360 has suggested that the industry be on the lookout for situations that offer increased opportunities for counterfeiting. The 2008 heparin crisis was preceded by illness among the pigs in China from which the heparin active ingredient is extracted, leading to shortages and price peaks—a strong inducement for foul play. From now on, purchasers should see unusual events like sudden price peaks as an early warning, and use Rx-360 as a clearinghouse to alert other companies.

To date, more than 40 organizations have signed on to Rx-360. Of course, many companies not involved in this new consortium may be implementing strong measures within their own firms and networks to ensure supply chain security. Those efforts will be much more effective, however, if the industry and regulators approach the problem as an industry-wide threat and act together.

Laura Bush is the editor in chief of BioPharm International,

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here